ES2210463T3 - Agonistas de 5-ht1f. - Google Patents
Agonistas de 5-ht1f.Info
- Publication number
- ES2210463T3 ES2210463T3 ES97309106T ES97309106T ES2210463T3 ES 2210463 T3 ES2210463 T3 ES 2210463T3 ES 97309106 T ES97309106 T ES 97309106T ES 97309106 T ES97309106 T ES 97309106T ES 2210463 T3 ES2210463 T3 ES 2210463T3
- Authority
- ES
- Spain
- Prior art keywords
- pyrrolo
- amino
- pyridine
- phenyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 101710138086 5-hydroxytryptamine receptor 1F Proteins 0.000 title claims abstract description 12
- 102100036311 5-hydroxytryptamine receptor 1F Human genes 0.000 title claims abstract description 12
- 239000000556 agonist Substances 0.000 title abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 251
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- -1 C 1 -C 4 alkoxy Chemical group 0.000 claims description 120
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 61
- 125000000217 alkyl group Chemical group 0.000 claims description 51
- 125000003545 alkoxy group Chemical group 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 23
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 21
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 208000002193 Pain Diseases 0.000 claims description 18
- 206010015866 Extravasation Diseases 0.000 claims description 17
- 230000036251 extravasation Effects 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- 208000019695 Migraine disease Diseases 0.000 claims description 10
- 125000002947 alkylene group Chemical group 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 206010027599 migraine Diseases 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 230000005764 inhibitory process Effects 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- 150000001204 N-oxides Chemical class 0.000 claims description 7
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 125000004104 aryloxy group Chemical group 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 3
- ORJIHHLJBCQRBS-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]propanamide Chemical compound C12=NC(NC(=O)CC)=CC=C2NC=C1C1CCN(C)CC1 ORJIHHLJBCQRBS-UHFFFAOYSA-N 0.000 claims description 3
- 230000001537 neural effect Effects 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 150000004885 piperazines Chemical class 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000001425 triazolyl group Chemical group 0.000 claims description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 2
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000000532 dioxanyl group Chemical group 0.000 claims description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000004620 quinolinyl-N-oxide group Chemical group 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 140
- 239000000203 mixture Substances 0.000 abstract description 43
- 230000004913 activation Effects 0.000 abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 104
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 100
- LAOHESRIMKGEEK-UHFFFAOYSA-N 3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-amine Chemical compound C1CN(C)CCC1C1=CNC2=CC=C(N)N=C12 LAOHESRIMKGEEK-UHFFFAOYSA-N 0.000 description 77
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 52
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- 230000002829 reductive effect Effects 0.000 description 50
- 238000002844 melting Methods 0.000 description 43
- 230000008018 melting Effects 0.000 description 43
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 33
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 32
- 239000007787 solid Substances 0.000 description 31
- 239000000243 solution Substances 0.000 description 29
- 239000000047 product Substances 0.000 description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 22
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 22
- 239000011541 reaction mixture Substances 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
- 230000027455 binding Effects 0.000 description 19
- 239000012141 concentrate Substances 0.000 description 19
- 235000008504 concentrate Nutrition 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- VMCYEHPEFYPEMX-UHFFFAOYSA-N 3-piperidin-4-yl-1h-pyrrolo[3,2-b]pyridin-5-amine Chemical class C12=NC(N)=CC=C2NC=C1C1CCNCC1 VMCYEHPEFYPEMX-UHFFFAOYSA-N 0.000 description 14
- 125000005843 halogen group Chemical group 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 108010053303 serotonin 1F receptor Proteins 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 12
- 239000000538 analytical sample Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000006260 foam Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- NJMUUPUCFASQIY-UHFFFAOYSA-N tert-butyl 4-(5-amino-1h-pyrrolo[3,2-b]pyridin-3-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=CNC2=CC=C(N)N=C12 NJMUUPUCFASQIY-UHFFFAOYSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 10
- FUNPYCZDNCZXQT-UHFFFAOYSA-N 3-(1,2,3,6-tetrahydropyridin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-amine Chemical class C12=NC(N)=CC=C2NC=C1C1=CCNCC1 FUNPYCZDNCZXQT-UHFFFAOYSA-N 0.000 description 10
- ZKMWKEXDFNWIHM-UHFFFAOYSA-N 3-(1-ethylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-amine Chemical compound C1CN(CC)CCC1C1=CNC2=CC=C(N)N=C12 ZKMWKEXDFNWIHM-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000005984 hydrogenation reaction Methods 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 8
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 8
- 229940076279 serotonin Drugs 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000000908 ammonium hydroxide Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- OFTKFKYVSBNYEC-UHFFFAOYSA-N 2-furoyl chloride Chemical compound ClC(=O)C1=CC=CO1 OFTKFKYVSBNYEC-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 6
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 6
- 239000012948 isocyanate Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 5
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 5
- BGMZTBKXOFFTBJ-UHFFFAOYSA-N 6-methyl-5-nitropyridin-2-amine Chemical compound CC1=NC(N)=CC=C1[N+]([O-])=O BGMZTBKXOFFTBJ-UHFFFAOYSA-N 0.000 description 5
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 5
- 241000700198 Cavia Species 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 5
- 239000012346 acetyl chloride Substances 0.000 description 5
- 150000008064 anhydrides Chemical class 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- BTUIFMCWPFMNRG-UHFFFAOYSA-N furan-3-carbonyl chloride Chemical compound ClC(=O)C=1C=COC=1 BTUIFMCWPFMNRG-UHFFFAOYSA-N 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- 210000000427 trigeminal ganglion Anatomy 0.000 description 5
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 5
- HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- RTTSQSBCRXBLAU-UHFFFAOYSA-N carbamoyl bromide Chemical compound NC(Br)=O RTTSQSBCRXBLAU-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 150000002081 enamines Chemical class 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 150000002513 isocyanates Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000000018 receptor agonist Substances 0.000 description 4
- 229940044601 receptor agonist Drugs 0.000 description 4
- 239000003762 serotonin receptor affecting agent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- ANJMITTWHAIIIU-UHFFFAOYSA-N 3-(1-ethyl-3,6-dihydro-2h-pyridin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-amine Chemical compound C1N(CC)CCC(C=2C3=NC(N)=CC=C3NC=2)=C1 ANJMITTWHAIIIU-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 3
- 239000007868 Raney catalyst Substances 0.000 description 3
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
- 229910000564 Raney nickel Inorganic materials 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 238000010533 azeotropic distillation Methods 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000013877 carbamide Nutrition 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000021824 exploration behavior Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 150000002540 isothiocyanates Chemical class 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- RVHFPOQGJLIAAJ-UHFFFAOYSA-N n-[3-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]acetamide Chemical compound C1N(C)CCC(C=2C3=NC(NC(C)=O)=CC=C3NC=2)=C1 RVHFPOQGJLIAAJ-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000005062 synaptic transmission Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- NOEYQOAKBMZXFX-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridin-5-amine Chemical compound NC1=CC=C2NC=CC2=N1 NOEYQOAKBMZXFX-UHFFFAOYSA-N 0.000 description 2
- OFQCQIGMURIECL-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl]-2',6'-dimethylspiro[isoquinoline-4,4'-oxane]-1,3-dione;phosphoric acid Chemical compound OP(O)(O)=O.O=C1N(CCN(CC)CC)C(=O)C2=CC=CC=C2C21CC(C)OC(C)C2 OFQCQIGMURIECL-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QYCKCCBTXIWNKL-UHFFFAOYSA-N 3-(1-butylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-amine Chemical compound C1CN(CCCC)CCC1C1=CNC2=CC=C(N)N=C12 QYCKCCBTXIWNKL-UHFFFAOYSA-N 0.000 description 2
- VDFCYSIJRNRTTL-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-amine Chemical compound C1N(C)CCC(C=2C3=NC(N)=CC=C3NC=2)=C1 VDFCYSIJRNRTTL-UHFFFAOYSA-N 0.000 description 2
- SICGOZJVWBYTPC-UHFFFAOYSA-N 3-(1-methylpiperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-2-amine Chemical compound NC1=C(C2=NC=CC=C2N1)C1CCN(CC1)C SICGOZJVWBYTPC-UHFFFAOYSA-N 0.000 description 2
- WKUAUKJSTNHDRY-UHFFFAOYSA-N 3-(1-propan-2-ylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-amine Chemical compound C1CN(C(C)C)CCC1C1=CNC2=CC=C(N)N=C12 WKUAUKJSTNHDRY-UHFFFAOYSA-N 0.000 description 2
- ZXLNQDLENCTYSA-UHFFFAOYSA-N 3-(1-propylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-amine Chemical compound C1CN(CCC)CCC1C1=CNC2=CC=C(N)N=C12 ZXLNQDLENCTYSA-UHFFFAOYSA-N 0.000 description 2
- SXEAQMABLMDXCD-UHFFFAOYSA-N 3-bromo-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CC(Br)=C1 SXEAQMABLMDXCD-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 2
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 2
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 2
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 101000941893 Felis catus Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 210000000078 claw Anatomy 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- FCGKREFBCAZJMR-UHFFFAOYSA-N n-(1h-pyrrolo[3,2-b]pyridin-5-yl)acetamide Chemical compound CC(=O)NC1=CC=C2NC=CC2=N1 FCGKREFBCAZJMR-UHFFFAOYSA-N 0.000 description 2
- VCYDEUCPMLCHGS-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]acetamide Chemical compound C1CN(C)CCC1C1=CNC2=CC=C(NC(C)=O)N=C12 VCYDEUCPMLCHGS-UHFFFAOYSA-N 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229950009215 phenylbutanoic acid Drugs 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000010970 precious metal Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- CAEWJEXPFKNBQL-UHFFFAOYSA-N prop-2-enyl carbonochloridate Chemical compound ClC(=O)OCC=C CAEWJEXPFKNBQL-UHFFFAOYSA-N 0.000 description 2
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000862 serotonergic effect Effects 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 229960003708 sumatriptan Drugs 0.000 description 2
- 229960000658 sumatriptan succinate Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- GNSGYVASXNMOCA-UHFFFAOYSA-N tert-butyl 4-(5-amino-1h-pyrrolo[3,2-b]pyridin-3-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(C=2C3=NC(N)=CC=C3NC=2)=C1 GNSGYVASXNMOCA-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- PUTNYFUSRUMLAC-UHFFFAOYSA-N (3-butoxyphenyl) n-[3-[1-(2,2-dimethylpropyl)piperidin-4-yl]-1h-pyrrolo[3,2-b]pyridin-5-yl]carbamate Chemical compound CCCCOC1=CC=CC(OC(=O)NC=2N=C3C(C4CCN(CC(C)(C)C)CC4)=CNC3=CC=2)=C1 PUTNYFUSRUMLAC-UHFFFAOYSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- CDBSRKWUFSRBHC-BTJKTKAUSA-N (z)-but-2-enedioic acid;1-cyclopentyl-3-[3-(1-pentan-3-ylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]urea Chemical compound OC(=O)\C=C/C(O)=O.C1CN(C(CC)CC)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)NC1CCCC1 CDBSRKWUFSRBHC-BTJKTKAUSA-N 0.000 description 1
- ZUEGCTDXCINXIG-UHFFFAOYSA-N 1-(4-fluorophenyl)-3-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]urea Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)NC1=CC=C(F)C=C1 ZUEGCTDXCINXIG-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- XJXONCMHXWTWDB-UHFFFAOYSA-N 1-[2-amino-3-(1-pentan-3-ylpiperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]-2-methylpropan-1-one Chemical compound CC(C(=O)C1=CC=C2C(=N1)C(=C(N2)N)C1CCN(CC1)C(CC)CC)C XJXONCMHXWTWDB-UHFFFAOYSA-N 0.000 description 1
- YNWNMFBVJMNMEC-UHFFFAOYSA-N 1-[2-amino-3-(1-propan-2-ylpiperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]-2-cyclohexylethanone Chemical compound C1(CCCCC1)CC(=O)C1=CC=C2C(=N1)C(=C(N2)N)C1CCN(CC1)C(C)C YNWNMFBVJMNMEC-UHFFFAOYSA-N 0.000 description 1
- LNYASOHJCDZCOR-UHFFFAOYSA-N 1-[2-amino-3-(1-propylpiperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hex-3-en-1-one Chemical compound C(CC=CCC)(=O)C1=CC=C2C(=N1)C(=C(N2)N)C1CCN(CC1)CCC LNYASOHJCDZCOR-UHFFFAOYSA-N 0.000 description 1
- JPTGWAPGIHWKRX-UHFFFAOYSA-N 1-[3-(1-ethylpiperidin-4-yl)-1-(methylamino)pyrrolo[3,2-b]pyridin-5-yl]-2-methylbutan-1-one;2-phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1.C12=NC(C(=O)C(C)CC)=CC=C2N(NC)C=C1C1CCN(CC)CC1 JPTGWAPGIHWKRX-UHFFFAOYSA-N 0.000 description 1
- QFWSGUMKZGJUHQ-UHFFFAOYSA-N 1-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]-3-phenylurea Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)NC1=CC=CC=C1 QFWSGUMKZGJUHQ-UHFFFAOYSA-N 0.000 description 1
- HWPVZLKUTRWTAL-UHFFFAOYSA-N 1-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]-3-prop-2-enylurea Chemical compound C1CN(C)CCC1C1=CNC2=CC=C(NC(=O)NCC=C)N=C12 HWPVZLKUTRWTAL-UHFFFAOYSA-N 0.000 description 1
- JQGBKRKJBQUXGV-UHFFFAOYSA-N 1-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]-3-propan-2-ylurea Chemical compound C12=NC(NC(=O)NC(C)C)=CC=C2NC=C1C1CCN(C)CC1 JQGBKRKJBQUXGV-UHFFFAOYSA-N 0.000 description 1
- OMALOOSQPKJNLY-UHFFFAOYSA-N 1-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]-3-propylurea Chemical compound C12=NC(NC(=O)NCCC)=CC=C2NC=C1C1CCN(C)CC1 OMALOOSQPKJNLY-UHFFFAOYSA-N 0.000 description 1
- PUHMUWKSJKWQHC-UHFFFAOYSA-N 1-[3-(1-tert-butylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]-3-cyclooctylurea Chemical compound C1CN(C(C)(C)C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)NC1CCCCCCC1 PUHMUWKSJKWQHC-UHFFFAOYSA-N 0.000 description 1
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
- QEODEVXILLOIPU-UHFFFAOYSA-N 1-butyl-3-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]urea Chemical compound C12=NC(NC(=O)NCCCC)=CC=C2NC=C1C1CCN(C)CC1 QEODEVXILLOIPU-UHFFFAOYSA-N 0.000 description 1
- UEDZPRZNRZRBBJ-UHFFFAOYSA-N 1-butyl-3-[3-(1-propan-2-ylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]thiourea;prop-2-enoic acid Chemical compound OC(=O)C=C.C12=NC(NC(=S)NCCCC)=CC=C2NC=C1C1CCN(C(C)C)CC1 UEDZPRZNRZRBBJ-UHFFFAOYSA-N 0.000 description 1
- PWFPQHXDVYAZTO-UHFFFAOYSA-N 1-ethyl-1-methyl-3-[3-(1-pentan-2-ylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]urea Chemical compound C1CN(C(C)CCC)CCC1C1=CNC2=CC=C(NC(=O)N(C)CC)N=C12 PWFPQHXDVYAZTO-UHFFFAOYSA-N 0.000 description 1
- HHYKTEJMGFZLJD-UHFFFAOYSA-N 1-ethyl-3-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]thiourea Chemical compound C12=NC(NC(=S)NCC)=CC=C2NC=C1C1CCN(C)CC1 HHYKTEJMGFZLJD-UHFFFAOYSA-N 0.000 description 1
- KDSSRYODOUSZPU-UHFFFAOYSA-N 1-ethyl-3-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]urea Chemical compound C12=NC(NC(=O)NCC)=CC=C2NC=C1C1CCN(C)CC1 KDSSRYODOUSZPU-UHFFFAOYSA-N 0.000 description 1
- OQURWGJAWSLGQG-UHFFFAOYSA-N 1-isocyanatopropane Chemical compound CCCN=C=O OQURWGJAWSLGQG-UHFFFAOYSA-N 0.000 description 1
- OPIDMBKDLIZFRZ-UHFFFAOYSA-N 1-methyl-3-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]urea Chemical compound C12=NC(NC(=O)NC)=CC=C2NC=C1C1CCN(C)CC1 OPIDMBKDLIZFRZ-UHFFFAOYSA-N 0.000 description 1
- QLSWIGRIBOSFMV-UHFFFAOYSA-N 1h-pyrrol-2-amine Chemical compound NC1=CC=CN1 QLSWIGRIBOSFMV-UHFFFAOYSA-N 0.000 description 1
- NSOAEFVYHIEIIB-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine;hydrochloride Chemical compound Cl.C1=CC=C2NC=CC2=N1 NSOAEFVYHIEIIB-UHFFFAOYSA-N 0.000 description 1
- YXYCGGPLERWVKQ-UHFFFAOYSA-N 2,2-dimethyl-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]propanamide Chemical compound C1CN(C)CCC1C1=CNC2=CC=C(NC(=O)C(C)(C)C)N=C12 YXYCGGPLERWVKQ-UHFFFAOYSA-N 0.000 description 1
- RZRHIWQOHAVXDR-UHFFFAOYSA-N 2,3,4,5,6-pentafluoro-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=C(F)C(F)=C(F)C(F)=C1F RZRHIWQOHAVXDR-UHFFFAOYSA-N 0.000 description 1
- HPBMISJSNWXYJF-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;n-[3-(1-propylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound OC(=O)C(O)C(O)C(O)=O.C1CN(CCC)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CC=C1 HPBMISJSNWXYJF-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- DOKHVHLEDMRUBD-UHFFFAOYSA-N 2,4,5-trifluoro-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC(F)=C(F)C=C1F DOKHVHLEDMRUBD-UHFFFAOYSA-N 0.000 description 1
- QIDPSTINRHXLAQ-UHFFFAOYSA-N 2,4-dichloro-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=C(Cl)C=C1Cl QIDPSTINRHXLAQ-UHFFFAOYSA-N 0.000 description 1
- 125000006334 2,4-difluoro benzoyl group Chemical group [H]C1=C([H])C(C(*)=O)=C(F)C([H])=C1F 0.000 description 1
- OLBJJNZQUDFJRR-UHFFFAOYSA-N 2,4-difluoro-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=C(F)C=C1F OLBJJNZQUDFJRR-UHFFFAOYSA-N 0.000 description 1
- PIFOGRYXTJNLOH-UHFFFAOYSA-N 2,5-dimethyl-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]-1,3-thiazole-4-carboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=C(C)SC(C)=N1 PIFOGRYXTJNLOH-UHFFFAOYSA-N 0.000 description 1
- HCDVSPLIKFZOIE-UHFFFAOYSA-N 2,6-difluoro-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=C(F)C=CC=C1F HCDVSPLIKFZOIE-UHFFFAOYSA-N 0.000 description 1
- WOFBXPXTLKSTCV-UHFFFAOYSA-N 2-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[3,2-b]pyridine Chemical group N1CCC(=CC1)C1=CC2=NC=CC=C2N1 WOFBXPXTLKSTCV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- DDBIRQWVHISYKS-UHFFFAOYSA-N 2-bromo-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CC=C1Br DDBIRQWVHISYKS-UHFFFAOYSA-N 0.000 description 1
- QZPLCQIWPZQETE-UHFFFAOYSA-N 2-chloro-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CC=C1Cl QZPLCQIWPZQETE-UHFFFAOYSA-N 0.000 description 1
- SSYRJEJCZCJKOF-UHFFFAOYSA-N 2-chloro-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CN=C1Cl SSYRJEJCZCJKOF-UHFFFAOYSA-N 0.000 description 1
- POQPJODLOCYAPE-UHFFFAOYSA-N 2-fluoro-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]-4-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=C(C(F)(F)F)C=C1F POQPJODLOCYAPE-UHFFFAOYSA-N 0.000 description 1
- HUIKYZOZYAWSKD-UHFFFAOYSA-N 2-fluoro-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CC=C1F HUIKYZOZYAWSKD-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- GSLTVFIVJMCNBH-UHFFFAOYSA-N 2-isocyanatopropane Chemical compound CC(C)N=C=O GSLTVFIVJMCNBH-UHFFFAOYSA-N 0.000 description 1
- KAKUZBQFLJYLJD-UHFFFAOYSA-N 2-methoxy-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound COC1=CC=CC=C1C(=O)NC1=CC=C(NC=C2C3CCN(C)CC3)C2=N1 KAKUZBQFLJYLJD-UHFFFAOYSA-N 0.000 description 1
- WSZSOPNGNAEERM-UHFFFAOYSA-N 2-methyl-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CC=C1C WSZSOPNGNAEERM-UHFFFAOYSA-N 0.000 description 1
- AUCWQHUTEPUQFG-UHFFFAOYSA-N 2-methyl-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]propanamide Chemical compound C12=NC(NC(=O)C(C)C)=CC=C2NC=C1C1CCN(C)CC1 AUCWQHUTEPUQFG-UHFFFAOYSA-N 0.000 description 1
- OORQLNFTOGLZOL-UHFFFAOYSA-N 2-methylpropyl n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]carbamate Chemical compound C12=NC(NC(=O)OCC(C)C)=CC=C2NC=C1C1CCN(C)CC1 OORQLNFTOGLZOL-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- YXOONVMKPZCUMS-UHFFFAOYSA-N 2-propoxyethyl n-[3-(1-ethylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]carbamate Chemical compound C12=NC(NC(=O)OCCOCCC)=CC=C2NC=C1C1CCN(CC)CC1 YXOONVMKPZCUMS-UHFFFAOYSA-N 0.000 description 1
- LYFYWXLKKQIOKO-UHFFFAOYSA-N 3,3-diaminopentan-1-ol Chemical compound CCC(N)(N)CCO LYFYWXLKKQIOKO-UHFFFAOYSA-N 0.000 description 1
- IGSLMQUXUUUXMG-UHFFFAOYSA-N 3,4-difluoro-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=C(F)C(F)=C1 IGSLMQUXUUUXMG-UHFFFAOYSA-N 0.000 description 1
- CIRSPTXGPFAXRE-UHFFFAOYSA-N 3-(1,2,3,6-tetrahydropyridin-4-yl)-1h-indole Chemical compound C1NCCC(C=2C3=CC=CC=C3NC=2)=C1 CIRSPTXGPFAXRE-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- RCZUKXCWOQRBTL-UHFFFAOYSA-N 3-[3-(1-butan-2-ylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]-1-phenyl-1-propan-2-ylurea Chemical compound C1CN(C(C)CC)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)N(C(C)C)C1=CC=CC=C1 RCZUKXCWOQRBTL-UHFFFAOYSA-N 0.000 description 1
- PEEPIFKEKSMNRB-UHFFFAOYSA-N 3-[3-(1-butylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]-1,1-di(propan-2-yl)urea Chemical compound C1CN(CCCC)CCC1C1=CNC2=CC=C(NC(=O)N(C(C)C)C(C)C)N=C12 PEEPIFKEKSMNRB-UHFFFAOYSA-N 0.000 description 1
- UBXAMALJHUJBPF-UHFFFAOYSA-N 3-[3-(1-butylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]-1-ethyl-1-phenylurea Chemical compound C1CN(CCCC)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)N(CC)C1=CC=CC=C1 UBXAMALJHUJBPF-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SBTPTNZZFVJDGA-UHFFFAOYSA-N 3-[3-[1-(2,2-dimethylpropyl)piperidin-4-yl]-1h-pyrrolo[3,2-b]pyridin-5-yl]-1-methyl-1-propan-2-ylurea Chemical compound C12=NC(NC(=O)N(C)C(C)C)=CC=C2NC=C1C1CCN(CC(C)(C)C)CC1 SBTPTNZZFVJDGA-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- HWTZUFXVCMWQFM-UHFFFAOYSA-N 3-bromo-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]thiophene-2-carboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=C(Br)C=CS1 HWTZUFXVCMWQFM-UHFFFAOYSA-N 0.000 description 1
- NYYRRBOMNHUCLB-UHFFFAOYSA-N 3-chloro-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCCl NYYRRBOMNHUCLB-UHFFFAOYSA-N 0.000 description 1
- GLQLJRCQOIZOJA-UHFFFAOYSA-N 3-chloro-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CC(Cl)=C1 GLQLJRCQOIZOJA-UHFFFAOYSA-N 0.000 description 1
- GXNSDTKXMVSVQL-UHFFFAOYSA-N 3-chloro-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]thiophene-2-carboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=C(Cl)C=CS1 GXNSDTKXMVSVQL-UHFFFAOYSA-N 0.000 description 1
- NOXKXEGQEYPIPO-UHFFFAOYSA-N 3-cyano-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CC(C#N)=C1 NOXKXEGQEYPIPO-UHFFFAOYSA-N 0.000 description 1
- ZOQSROUPADLHKR-UHFFFAOYSA-N 3-fluoro-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CC(F)=C1 ZOQSROUPADLHKR-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- IJFXRHURBJZNAO-UHFFFAOYSA-M 3-hydroxybenzoate Chemical compound OC1=CC=CC(C([O-])=O)=C1 IJFXRHURBJZNAO-UHFFFAOYSA-M 0.000 description 1
- BLGQPNNQPFYPEQ-UHFFFAOYSA-N 3-methoxy-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound COC1=CC=CC(C(=O)NC=2N=C3C(C4CCN(C)CC4)=CNC3=CC=2)=C1 BLGQPNNQPFYPEQ-UHFFFAOYSA-N 0.000 description 1
- JZEMGYDWCXCAQQ-UHFFFAOYSA-N 3-methyl-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CC(C)=C1 JZEMGYDWCXCAQQ-UHFFFAOYSA-N 0.000 description 1
- IVLUGWZZNXVBHY-UHFFFAOYSA-N 3-methyl-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]butanamide Chemical compound C12=NC(NC(=O)CC(C)C)=CC=C2NC=C1C1CCN(C)CC1 IVLUGWZZNXVBHY-UHFFFAOYSA-N 0.000 description 1
- UYDRQDUIDISYCJ-UHFFFAOYSA-N 3-methyl-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]thiophene-2-carboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=C(C)C=CS1 UYDRQDUIDISYCJ-UHFFFAOYSA-N 0.000 description 1
- ISULZYQDGYXDFW-UHFFFAOYSA-N 3-methylbutanoyl chloride Chemical compound CC(C)CC(Cl)=O ISULZYQDGYXDFW-UHFFFAOYSA-N 0.000 description 1
- NXTNASSYJUXJDV-UHFFFAOYSA-N 3-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(C(Cl)=O)=C1 NXTNASSYJUXJDV-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- LNPSXIVOXXSMHC-UHFFFAOYSA-N 4-[2-amino-3-(1-butan-2-ylpiperidin-4-yl)-1H-pyrrolo[3,2-b]pyridine-5-carbonyl]benzaldehyde Chemical compound C(=O)C1=CC=C(C(=O)C2=CC=C3C(=N2)C(=C(N3)N)C2CCN(CC2)C(C)CC)C=C1 LNPSXIVOXXSMHC-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- 125000002672 4-bromobenzoyl group Chemical group BrC1=CC=C(C(=O)*)C=C1 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-M 4-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-M 0.000 description 1
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 1
- CDOSRLXPFHPFFJ-UHFFFAOYSA-N 4-cyano-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=C(C#N)C=C1 CDOSRLXPFHPFFJ-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- PFYBRKGVXVKJNQ-UHFFFAOYSA-N 4-fluoro-n-(3-piperidin-4-yl-1h-pyrrolo[3,2-b]pyridin-5-yl)benzamide Chemical compound C1=CC(F)=CC=C1C(=O)NC1=CC=C(NC=C2C3CCNCC3)C2=N1 PFYBRKGVXVKJNQ-UHFFFAOYSA-N 0.000 description 1
- RUJUSCZEDDAGAW-UHFFFAOYSA-N 4-fluoro-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=C(F)C=C1 RUJUSCZEDDAGAW-UHFFFAOYSA-N 0.000 description 1
- NBKQASQZUBJMEM-UHFFFAOYSA-N 4-fluoro-n-[3-(1-propan-2-ylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C(C)C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=C(F)C=C1 NBKQASQZUBJMEM-UHFFFAOYSA-N 0.000 description 1
- AGNQRCZHJFDENL-UHFFFAOYSA-N 4-fluoro-n-[3-(1-propylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(CCC)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=C(F)C=C1 AGNQRCZHJFDENL-UHFFFAOYSA-N 0.000 description 1
- NJAKCIUOTIPYED-UHFFFAOYSA-N 4-iodobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(I)C=C1 NJAKCIUOTIPYED-UHFFFAOYSA-N 0.000 description 1
- WLNPZJZFXOHFPO-UHFFFAOYSA-N 4-methoxy-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=C(NC=C2C3CCN(C)CC3)C2=N1 WLNPZJZFXOHFPO-UHFFFAOYSA-N 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
- MZAJSRFHJVVBKJ-UHFFFAOYSA-N 4-methoxybutyl n-[2-(1-ethylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]carbamate Chemical compound C1CN(CC)CCC1C1=CC2=NC(NC(=O)OCCCCOC)=CC=C2N1 MZAJSRFHJVVBKJ-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- VQGMYZTZXCOYRW-UHFFFAOYSA-N 4-methyl-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=C(C)C=C1 VQGMYZTZXCOYRW-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- VGDJKPRPPMPIKQ-UHFFFAOYSA-N 4-tert-butyl-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=C(C(C)(C)C)C=C1 VGDJKPRPPMPIKQ-UHFFFAOYSA-N 0.000 description 1
- 108091005478 5-HT1 receptors Proteins 0.000 description 1
- 102000035038 5-HT1 receptors Human genes 0.000 description 1
- WRUCPMJCNKRCSR-UHFFFAOYSA-N 5-[2-amino-3-(1-methylpiperidin-4-yl)-1H-pyrrolo[3,2-b]pyridine-5-carbonyl]quinoline-2-carbonitrile Chemical compound C(#N)C1=NC=2C=CC=C(C2C=C1)C(=O)C1=CC=C2C(=N1)C(=C(N2)N)C2CCN(CC2)C WRUCPMJCNKRCSR-UHFFFAOYSA-N 0.000 description 1
- QYIKMLWDEAQABR-UHFFFAOYSA-N 5-chloro-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]thiophene-2-carboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=C(Cl)S1 QYIKMLWDEAQABR-UHFFFAOYSA-N 0.000 description 1
- UJVWMPXREOEGSL-UHFFFAOYSA-N 5-fluoro-3-[1-[2-(1-methylpyrazol-4-yl)ethyl]piperidin-4-yl]-1h-indole;hydrochloride Chemical compound Cl.C1=NN(C)C=C1CCN1CCC(C=2C3=CC(F)=CC=C3NC=2)CC1 UJVWMPXREOEGSL-UHFFFAOYSA-N 0.000 description 1
- XDKYTGOOWCPJKB-UHFFFAOYSA-N 5-fluoro-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]thiophene-2-carboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=C(F)S1 XDKYTGOOWCPJKB-UHFFFAOYSA-N 0.000 description 1
- UCXNLBJDJNYDEP-UHFFFAOYSA-N 5-methyl-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]thiophene-2-carboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=C(C)S1 UCXNLBJDJNYDEP-UHFFFAOYSA-N 0.000 description 1
- ZQUXUQXIXIVEQA-UHFFFAOYSA-N 6-(dimethylamino)-6,7,8,9-tetrahydro-5h-carbazol-3-ol Chemical compound N1C2=CC=C(O)C=C2C2=C1CCC(N(C)C)C2 ZQUXUQXIXIVEQA-UHFFFAOYSA-N 0.000 description 1
- JPQIQEFPXXVMTN-UHFFFAOYSA-N 6-chloro-n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=C(Cl)N=C1 JPQIQEFPXXVMTN-UHFFFAOYSA-N 0.000 description 1
- ZIIGSRYPZWDGBT-UHFFFAOYSA-N 610-30-0 Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O ZIIGSRYPZWDGBT-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- GJTXHESFKJDOFH-UHFFFAOYSA-N 8-chloro-n,n-diethyl-1,2,3,4-tetrahydronaphthalen-2-amine;hydrochloride Chemical compound Cl.C1=CC(Cl)=C2CC(N(CC)CC)CCC2=C1 GJTXHESFKJDOFH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- KWHVCUDGOYUMDP-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)C1=C(C(=O)C2=CC=C3C(=N2)C(=C(N3)N)C3CCN(CC3)CCCCC)C=CC=C1 Chemical compound C(C1=CC=CC=C1)(=O)C1=C(C(=O)C2=CC=C3C(=N2)C(=C(N3)N)C3CCN(CC3)CCCCC)C=CC=C1 KWHVCUDGOYUMDP-UHFFFAOYSA-N 0.000 description 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 1
- HIGASMIUSVROPF-UHFFFAOYSA-N C=1C=CC=CC=1N(C(=O)OCC)C(=O)NC(N=C12)=CC=C1NC=C2C1CCN(C(C)(C)C)CC1 Chemical compound C=1C=CC=CC=1N(C(=O)OCC)C(=O)NC(N=C12)=CC=C1NC=C2C1CCN(C(C)(C)C)CC1 HIGASMIUSVROPF-UHFFFAOYSA-N 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241001459693 Dipterocarpus zeylanicus Species 0.000 description 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 244000257039 Duranta repens Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000783605 Homo sapiens 5-hydroxytryptamine receptor 1F Proteins 0.000 description 1
- 208000030990 Impulse-control disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028403 Mutism Diseases 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- NUVBLZNALSPLQW-UHFFFAOYSA-N NC1=C(C2=NC=CC=C2N1)C1CCN(CC1)C(C)(C)C Chemical compound NC1=C(C2=NC=CC=C2N1)C1CCN(CC1)C(C)(C)C NUVBLZNALSPLQW-UHFFFAOYSA-N 0.000 description 1
- HCLINMUWJMXBKR-UHFFFAOYSA-N NC1=C(C2=NC=CC=C2N1)C1CCN(CC1)CC(C)(C)C Chemical compound NC1=C(C2=NC=CC=C2N1)C1CCN(CC1)CC(C)(C)C HCLINMUWJMXBKR-UHFFFAOYSA-N 0.000 description 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100026450 POU domain, class 3, transcription factor 4 Human genes 0.000 description 1
- 101710133389 POU domain, class 3, transcription factor 4 Proteins 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 206010043903 Tobacco abuse Diseases 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- LPEDVQTWDMTZKE-UHFFFAOYSA-N [1-(butylamino)-3-(1-ethylpiperidin-4-yl)pyrrolo[3,2-b]pyridin-5-yl]-thiophen-2-ylmethanone Chemical compound C12=NC(C(=O)C=3SC=CC=3)=CC=C2N(NCCCC)C=C1C1CCN(CC)CC1 LPEDVQTWDMTZKE-UHFFFAOYSA-N 0.000 description 1
- YJKCXDVLTMJDIQ-UHFFFAOYSA-N [2-amino-3-(1-butylpiperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]-(2-methylsulfonylphenyl)methanone Chemical compound CS(=O)(=O)C1=C(C(=O)C2=CC=C3C(=N2)C(=C(N3)N)C2CCN(CC2)CCCC)C=CC=C1 YJKCXDVLTMJDIQ-UHFFFAOYSA-N 0.000 description 1
- RKOPZNKSKWSTGN-UHFFFAOYSA-N [2-amino-3-(1-butylpiperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]-(furan-3-yl)methanone Chemical compound O1C=C(C=C1)C(=O)C1=CC=C2C(=N1)C(=C(N2)N)C1CCN(CC1)CCCC RKOPZNKSKWSTGN-UHFFFAOYSA-N 0.000 description 1
- IKELOCACDMNZRM-UHFFFAOYSA-N [2-amino-3-(1-ethyl-3,4-dihydro-2H-pyridin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]-(4-fluorophenyl)methanone Chemical compound FC1=CC=C(C(=O)C2=CC=C3C(=N2)C(=C(N3)N)C2CCN(C=C2)CC)C=C1 IKELOCACDMNZRM-UHFFFAOYSA-N 0.000 description 1
- SETYFBHDEDZHEP-UHFFFAOYSA-N [2-amino-3-(1-ethylpiperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]-thiophen-3-ylmethanone Chemical compound S1C=C(C=C1)C(=O)C1=CC=C2C(=N1)C(=C(N2)N)C1CCN(CC1)CC SETYFBHDEDZHEP-UHFFFAOYSA-N 0.000 description 1
- OVWOKCPKZMZQMC-UHFFFAOYSA-N [2-amino-3-(1-hexylpiperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]-(1,3-oxazol-2-yl)methanone Chemical compound O1C(=NC=C1)C(=O)C1=CC=C2C(=N1)C(=C(N2)N)C1CCN(CC1)CCCCCC OVWOKCPKZMZQMC-UHFFFAOYSA-N 0.000 description 1
- ANJNZOFWWBRJTD-UHFFFAOYSA-N [2-amino-3-(1-hexylpiperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]-thiophen-2-ylmethanone Chemical compound S1C(=CC=C1)C(=O)C1=CC=C2C(=N1)C(=C(N2)N)C1CCN(CC1)CCCCCC ANJNZOFWWBRJTD-UHFFFAOYSA-N 0.000 description 1
- VPHPEBFIGGGYTG-UHFFFAOYSA-N [2-amino-3-(1-methylpiperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]-(1,2-oxazol-5-yl)methanone Chemical compound O1N=CC=C1C(=O)C1=CC=C2C(=N1)C(=C(N2)N)C1CCN(CC1)C VPHPEBFIGGGYTG-UHFFFAOYSA-N 0.000 description 1
- CNJRALYMKBHNPO-UHFFFAOYSA-N [2-amino-3-(1-methylpiperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]-(1H-pyrazol-4-yl)methanone Chemical compound N1N=CC(=C1)C(=O)C1=CC=C2C(=N1)C(=C(N2)N)C1CCN(CC1)C CNJRALYMKBHNPO-UHFFFAOYSA-N 0.000 description 1
- CRUPRGCYEPOZBX-UHFFFAOYSA-N [2-amino-3-(1-methylpiperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]-(1H-pyrrol-3-yl)methanone Chemical compound N1C=C(C=C1)C(=O)C1=CC=C2C(=N1)C(=C(N2)N)C1CCN(CC1)C CRUPRGCYEPOZBX-UHFFFAOYSA-N 0.000 description 1
- MCAAUODYDWVPRN-UHFFFAOYSA-N [2-amino-3-(1-methylpiperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]-(2-chloropyridin-4-yl)methanone Chemical compound ClC1=NC=CC(=C1)C(=O)C1=CC=C2C(=N1)C(=C(N2)N)C1CCN(CC1)C MCAAUODYDWVPRN-UHFFFAOYSA-N 0.000 description 1
- BDODAYQYXNMLHT-UHFFFAOYSA-N [2-amino-3-(1-methylpiperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]-(2-methoxypyrimidin-4-yl)methanone Chemical compound COC1=NC=CC(=N1)C(=O)C1=CC=C2C(=N1)C(=C(N2)N)C1CCN(CC1)C BDODAYQYXNMLHT-UHFFFAOYSA-N 0.000 description 1
- RAHDIWCUKBGVAN-UHFFFAOYSA-N [2-amino-3-(1-methylpiperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]-(2-methyl-1,3-oxazol-4-yl)methanone Chemical compound CC=1OC=C(N=1)C(=O)C1=CC=C2C(=N1)C(=C(N2)N)C1CCN(CC1)C RAHDIWCUKBGVAN-UHFFFAOYSA-N 0.000 description 1
- LITXKKJZUDSVGQ-UHFFFAOYSA-N [2-amino-3-(1-methylpiperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]-quinolin-2-ylmethanone Chemical compound N1=C(C=CC2=CC=CC=C12)C(=O)C1=CC=C2C(=N1)C(=C(N2)N)C1CCN(CC1)C LITXKKJZUDSVGQ-UHFFFAOYSA-N 0.000 description 1
- MJHWOCPBKGJCCR-UHFFFAOYSA-N [2-amino-3-(1-propan-2-yl-3,4-dihydro-2H-pyridin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]-(furan-2-yl)methanone Chemical compound O1C(=CC=C1)C(=O)C1=CC=C2C(=N1)C(=C(N2)N)C1CCN(C=C1)C(C)C MJHWOCPBKGJCCR-UHFFFAOYSA-N 0.000 description 1
- QMUMYSVTRIFYFK-UHFFFAOYSA-N [2-amino-3-(1-propan-2-ylpiperidin-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]-thiophen-2-ylmethanone Chemical compound S1C(=CC=C1)C(=O)C1=CC=C2C(=N1)C(=C(N2)N)C1CCN(CC1)C(C)C QMUMYSVTRIFYFK-UHFFFAOYSA-N 0.000 description 1
- CWJVMAZFEOFECV-UHFFFAOYSA-N [2-amino-3-[1-(2,2-dimethylpropyl)piperidin-4-yl]-1H-pyrrolo[3,2-b]pyridin-5-yl]-(furan-2-yl)methanone Chemical compound O1C(=CC=C1)C(=O)C1=CC=C2C(=N1)C(=C(N2)N)C1CCN(CC1)CC(C)(C)C CWJVMAZFEOFECV-UHFFFAOYSA-N 0.000 description 1
- YQKFJYBRZVNXKQ-UHFFFAOYSA-N [Na].BC#N Chemical compound [Na].BC#N YQKFJYBRZVNXKQ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 101150024767 arnT gene Proteins 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- VVJWYEXBMCCURU-UHFFFAOYSA-N but-2-enyl n-[3-(1,2,3,4-tetrahydropyridin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]carbamate Chemical compound C12=NC(NC(=O)OCC=CC)=CC=C2NC=C1C1CCNC=C1 VVJWYEXBMCCURU-UHFFFAOYSA-N 0.000 description 1
- HFVVAWQCEGFTMC-UHFFFAOYSA-N butan-2-yl n-phenyl-n-[[3-(1-propylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]carbamoyl]carbamate Chemical compound C1CN(CCC)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)N(C(=O)OC(C)CC)C1=CC=CC=C1 HFVVAWQCEGFTMC-UHFFFAOYSA-N 0.000 description 1
- KVZMYAMZTRXTRT-UHFFFAOYSA-N butanedioic acid;1-hexyl-3-[3-(1-propylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]urea Chemical compound OC(=O)CCC(O)=O.C12=NC(NC(=O)NCCCCCC)=CC=C2NC=C1C1CCN(CCC)CC1 KVZMYAMZTRXTRT-UHFFFAOYSA-N 0.000 description 1
- OCNUDCXIVFNBOZ-UHFFFAOYSA-N butyl n-[3-(1-propyl-3,4-dihydro-2h-pyridin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]carbamate Chemical compound C12=NC(NC(=O)OCCCC)=CC=C2NC=C1C1CCN(CCC)C=C1 OCNUDCXIVFNBOZ-UHFFFAOYSA-N 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- JFWMYCVMQSLLOO-UHFFFAOYSA-N cyclobutanecarbonyl chloride Chemical compound ClC(=O)C1CCC1 JFWMYCVMQSLLOO-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- RVOJTCZRIKWHDX-UHFFFAOYSA-N cyclohexanecarbonyl chloride Chemical compound ClC(=O)C1CCCCC1 RVOJTCZRIKWHDX-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- CSQSZOCXOQEROT-UHFFFAOYSA-N cyclohexyl n-[3-[1-(2-methylpropyl)piperidin-4-yl]-1h-pyrrolo[3,2-b]pyridin-5-yl]carbamate Chemical compound C1CN(CC(C)C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)OC1CCCCC1 CSQSZOCXOQEROT-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- PDQFAZOHVDTZDD-UHFFFAOYSA-N cyclooctyl n-[3-(1-propan-2-ylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]carbamate Chemical compound C1CN(C(C)C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)OC1CCCCCCC1 PDQFAZOHVDTZDD-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- YUFAUSXZMDPBBD-UHFFFAOYSA-N cyclopropyl n-[3-(1-tert-butylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]carbamate Chemical compound C1CN(C(C)(C)C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)OC1CC1 YUFAUSXZMDPBBD-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- JFCHCEVFVPMVDJ-UHFFFAOYSA-N ethyl n-[3-(1-ethyl-3,6-dihydro-2h-pyridin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]carbamate Chemical compound C12=NC(NC(=O)OCC)=CC=C2NC=C1C1=CCN(CC)CC1 JFCHCEVFVPMVDJ-UHFFFAOYSA-N 0.000 description 1
- DMCLFACPZAPKSJ-UHFFFAOYSA-N ethyl n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]carbamate Chemical compound C12=NC(NC(=O)OCC)=CC=C2NC=C1C1CCN(C)CC1 DMCLFACPZAPKSJ-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- YWGHUJQYGPDNKT-UHFFFAOYSA-N hexanoyl chloride Chemical compound CCCCCC(Cl)=O YWGHUJQYGPDNKT-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 229940090436 imitrex Drugs 0.000 description 1
- 210000004283 incisor Anatomy 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011850 initial investigation Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- YXLXNTZUUITOCE-UHFFFAOYSA-N methyl 4-[[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]amino]-4-oxobutanoate Chemical compound C12=NC(NC(=O)CCC(=O)OC)=CC=C2NC=C1C1CCN(C)CC1 YXLXNTZUUITOCE-UHFFFAOYSA-N 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- MUMVIYLVHVCYGI-UHFFFAOYSA-N n,n,n',n',n",n"-hexamethylmethanetriamine Chemical compound CN(C)C(N(C)C)N(C)C MUMVIYLVHVCYGI-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- LXZJUOMETYSHFR-UHFFFAOYSA-N n-(3-piperidin-4-yl-1h-pyrrolo[3,2-b]pyridin-5-yl)acetamide Chemical compound C12=NC(NC(=O)C)=CC=C2NC=C1C1CCNCC1 LXZJUOMETYSHFR-UHFFFAOYSA-N 0.000 description 1
- GWUUPZWMKPQLDV-UHFFFAOYSA-N n-(3-piperidin-4-yl-1h-pyrrolo[3,2-b]pyridin-5-yl)benzamide Chemical compound C=1C=CC=CC=1C(=O)NC(N=C12)=CC=C1NC=C2C1CCNCC1 GWUUPZWMKPQLDV-UHFFFAOYSA-N 0.000 description 1
- SSUBQGFSVJJLEC-UHFFFAOYSA-N n-(3-piperidin-4-yl-1h-pyrrolo[3,2-b]pyridin-5-yl)cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(N=C12)=CC=C1NC=C2C1CCNCC1 SSUBQGFSVJJLEC-UHFFFAOYSA-N 0.000 description 1
- CPYRCGXATQQPCI-UHFFFAOYSA-N n-(3-piperidin-4-yl-1h-pyrrolo[3,2-b]pyridin-5-yl)furan-2-carboxamide Chemical compound C=1C=COC=1C(=O)NC(N=C12)=CC=C1NC=C2C1CCNCC1 CPYRCGXATQQPCI-UHFFFAOYSA-N 0.000 description 1
- HOJJRMASLDKPPF-UHFFFAOYSA-N n-(3-piperidin-4-yl-1h-pyrrolo[3,2-b]pyridin-5-yl)furan-3-carboxamide Chemical compound C1=COC=C1C(=O)NC(N=C12)=CC=C1NC=C2C1CCNCC1 HOJJRMASLDKPPF-UHFFFAOYSA-N 0.000 description 1
- WSXYJBWPQGSQLD-UHFFFAOYSA-N n-(3-piperidin-4-yl-1h-pyrrolo[3,2-b]pyridin-5-yl)propanamide Chemical compound C12=NC(NC(=O)CC)=CC=C2NC=C1C1CCNCC1 WSXYJBWPQGSQLD-UHFFFAOYSA-N 0.000 description 1
- JUFULMAHRDARAA-UHFFFAOYSA-N n-(3-piperidin-4-yl-1h-pyrrolo[3,2-b]pyridin-5-yl)pyridine-4-carboxamide Chemical compound C=1C=NC=CC=1C(=O)NC(N=C12)=CC=C1NC=C2C1CCNCC1 JUFULMAHRDARAA-UHFFFAOYSA-N 0.000 description 1
- LOQHVIVSEPCOGN-UHFFFAOYSA-N n-(3-piperidin-4-yl-1h-pyrrolo[3,2-b]pyridin-5-yl)thiophene-2-carboxamide Chemical compound C=1C=CSC=1C(=O)NC(N=C12)=CC=C1NC=C2C1CCNCC1 LOQHVIVSEPCOGN-UHFFFAOYSA-N 0.000 description 1
- BTPMJHBWNVFOSK-UHFFFAOYSA-N n-(3-piperidin-4-yl-1h-pyrrolo[3,2-b]pyridin-5-yl)thiophene-3-carboxamide Chemical compound C1=CSC=C1C(=O)NC(N=C12)=CC=C1NC=C2C1CCNCC1 BTPMJHBWNVFOSK-UHFFFAOYSA-N 0.000 description 1
- SXEHINGRRBPCRH-UHFFFAOYSA-N n-[3-(1-butylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]-4-fluorobenzamide Chemical compound C1CN(CCCC)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=C(F)C=C1 SXEHINGRRBPCRH-UHFFFAOYSA-N 0.000 description 1
- ZUNVQVLYCUKKAB-UHFFFAOYSA-N n-[3-(1-butylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]propanamide Chemical compound C1CN(CCCC)CCC1C1=CNC2=CC=C(NC(=O)CC)N=C12 ZUNVQVLYCUKKAB-UHFFFAOYSA-N 0.000 description 1
- CINLYSVVMFMYQH-UHFFFAOYSA-N n-[3-(1-ethyl-3,6-dihydro-2h-pyridin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]acetamide Chemical compound C1N(CC)CCC(C=2C3=NC(NC(C)=O)=CC=C3NC=2)=C1 CINLYSVVMFMYQH-UHFFFAOYSA-N 0.000 description 1
- GNYKCVFTHZRFOY-UHFFFAOYSA-N n-[3-(1-ethyl-3,6-dihydro-2h-pyridin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1N(CC)CCC(C=2C3=NC(NC(=O)C=4C=CC=CC=4)=CC=C3NC=2)=C1 GNYKCVFTHZRFOY-UHFFFAOYSA-N 0.000 description 1
- QRQKQDNQBWVURV-UHFFFAOYSA-N n-[3-(1-ethyl-3,6-dihydro-2h-pyridin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]furan-2-carboxamide Chemical compound C1N(CC)CCC(C=2C3=NC(NC(=O)C=4OC=CC=4)=CC=C3NC=2)=C1 QRQKQDNQBWVURV-UHFFFAOYSA-N 0.000 description 1
- OTFJMXNBWQOBBN-UHFFFAOYSA-N n-[3-(1-ethyl-3,6-dihydro-2h-pyridin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]thiophene-2-carboxamide Chemical compound C1N(CC)CCC(C=2C3=NC(NC(=O)C=4SC=CC=4)=CC=C3NC=2)=C1 OTFJMXNBWQOBBN-UHFFFAOYSA-N 0.000 description 1
- QGXMSFNQAWXAHE-UHFFFAOYSA-N n-[3-(1-ethylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]-4-fluorobenzamide Chemical compound C1CN(CC)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=C(F)C=C1 QGXMSFNQAWXAHE-UHFFFAOYSA-N 0.000 description 1
- NAYKMPWPCHFLOW-UHFFFAOYSA-N n-[3-(1-ethylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]acetamide Chemical compound C1CN(CC)CCC1C1=CNC2=CC=C(NC(C)=O)N=C12 NAYKMPWPCHFLOW-UHFFFAOYSA-N 0.000 description 1
- WQBJDIHBTYYKKM-UHFFFAOYSA-N n-[3-(1-ethylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(CC)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CC=C1 WQBJDIHBTYYKKM-UHFFFAOYSA-N 0.000 description 1
- UVOMNPSIYBGDAR-UHFFFAOYSA-N n-[3-(1-ethylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]cyclopropanecarboxamide Chemical compound C1CN(CC)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1CC1 UVOMNPSIYBGDAR-UHFFFAOYSA-N 0.000 description 1
- IXLHIFFZQJABCQ-UHFFFAOYSA-N n-[3-(1-ethylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]furan-2-carboxamide Chemical compound C1CN(CC)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CO1 IXLHIFFZQJABCQ-UHFFFAOYSA-N 0.000 description 1
- PMGPBCVPWHOKQP-UHFFFAOYSA-N n-[3-(1-ethylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]furan-3-carboxamide Chemical compound C1CN(CC)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=COC=C1 PMGPBCVPWHOKQP-UHFFFAOYSA-N 0.000 description 1
- VKNSAWMJJAKELC-UHFFFAOYSA-N n-[3-(1-ethylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]propanamide Chemical compound C1CN(CC)CCC1C1=CNC2=CC=C(NC(=O)CC)N=C12 VKNSAWMJJAKELC-UHFFFAOYSA-N 0.000 description 1
- KXRALXQGJSBCLT-UHFFFAOYSA-N n-[3-(1-ethylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]pyridine-4-carboxamide Chemical compound C1CN(CC)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=NC=C1 KXRALXQGJSBCLT-UHFFFAOYSA-N 0.000 description 1
- QWNXRAUZIBUWQG-UHFFFAOYSA-N n-[3-(1-ethylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]thiophene-2-carboxamide Chemical compound C1CN(CC)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CS1 QWNXRAUZIBUWQG-UHFFFAOYSA-N 0.000 description 1
- RXKDQGIWZGIRKR-UHFFFAOYSA-N n-[3-(1-ethylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]thiophene-3-carboxamide Chemical compound C1CN(CC)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CSC=C1 RXKDQGIWZGIRKR-UHFFFAOYSA-N 0.000 description 1
- KUTPYRJCRMIKMN-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]-1-benzothiophene-2-carboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC2=CC=CC=C2S1 KUTPYRJCRMIKMN-UHFFFAOYSA-N 0.000 description 1
- KJPDLESBUJGYRH-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]-2-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CC=C1C(F)(F)F KJPDLESBUJGYRH-UHFFFAOYSA-N 0.000 description 1
- FXZBOGLCSOPCIH-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]-2-nitrobenzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CC=C1[N+]([O-])=O FXZBOGLCSOPCIH-UHFFFAOYSA-N 0.000 description 1
- HQXYOWRNDBMCID-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]-3-nitrobenzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CC([N+]([O-])=O)=C1 HQXYOWRNDBMCID-UHFFFAOYSA-N 0.000 description 1
- YJDFNBPJWSQQGH-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]-4-(trifluoromethoxy)benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=C(OC(F)(F)F)C=C1 YJDFNBPJWSQQGH-UHFFFAOYSA-N 0.000 description 1
- ZBKDVVVPQXEAPG-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]-4-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=C(C(F)(F)F)C=C1 ZBKDVVVPQXEAPG-UHFFFAOYSA-N 0.000 description 1
- JAYOKUDGYAUIEC-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]-4-nitrobenzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=C([N+]([O-])=O)C=C1 JAYOKUDGYAUIEC-UHFFFAOYSA-N 0.000 description 1
- NUJQRCYCAKYAGD-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]-5-nitrofuran-2-carboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=C([N+]([O-])=O)O1 NUJQRCYCAKYAGD-UHFFFAOYSA-N 0.000 description 1
- DNVFWFHVRZWNQC-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CC=C1 DNVFWFHVRZWNQC-UHFFFAOYSA-N 0.000 description 1
- CVLRQZHBNSZJNQ-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzenesulfonamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NS(=O)(=O)C1=CC=CC=C1 CVLRQZHBNSZJNQ-UHFFFAOYSA-N 0.000 description 1
- JJDBTUIYFOHXHH-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]butanamide Chemical compound C12=NC(NC(=O)CCC)=CC=C2NC=C1C1CCN(C)CC1 JJDBTUIYFOHXHH-UHFFFAOYSA-N 0.000 description 1
- CGNOEAKWDFGWNP-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]cyclobutanecarboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1CCC1 CGNOEAKWDFGWNP-UHFFFAOYSA-N 0.000 description 1
- XZPGIQSKRLUYSY-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]cyclohexanecarboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1CCCCC1 XZPGIQSKRLUYSY-UHFFFAOYSA-N 0.000 description 1
- ZWNFGXDUPNOZMG-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]cyclopentanecarboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1CCCC1 ZWNFGXDUPNOZMG-UHFFFAOYSA-N 0.000 description 1
- LVNGFTRMMWFHRF-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]cyclopropanecarboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1CC1 LVNGFTRMMWFHRF-UHFFFAOYSA-N 0.000 description 1
- YLMDJSLIPJEWKV-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]furan-2-carboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CO1 YLMDJSLIPJEWKV-UHFFFAOYSA-N 0.000 description 1
- BUNPANXQBOTFPV-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]furan-3-carboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=COC=C1 BUNPANXQBOTFPV-UHFFFAOYSA-N 0.000 description 1
- OYFCPNQKSRRLHS-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]hexanamide Chemical compound C12=NC(NC(=O)CCCCC)=CC=C2NC=C1C1CCN(C)CC1 OYFCPNQKSRRLHS-UHFFFAOYSA-N 0.000 description 1
- WXJVFUSXRRBQQK-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]octanamide Chemical compound C12=NC(NC(=O)CCCCCCC)=CC=C2NC=C1C1CCN(C)CC1 WXJVFUSXRRBQQK-UHFFFAOYSA-N 0.000 description 1
- YYWSIECGFQGNKL-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]pentanamide Chemical compound C12=NC(NC(=O)CCCC)=CC=C2NC=C1C1CCN(C)CC1 YYWSIECGFQGNKL-UHFFFAOYSA-N 0.000 description 1
- SVTBFKBDZPYGIL-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]pyridine-2-carboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CC=N1 SVTBFKBDZPYGIL-UHFFFAOYSA-N 0.000 description 1
- BEZDGDNPEBLBIO-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CN=C1 BEZDGDNPEBLBIO-UHFFFAOYSA-N 0.000 description 1
- UJDAYRGTKPOMIU-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]pyridine-4-carboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=NC=C1 UJDAYRGTKPOMIU-UHFFFAOYSA-N 0.000 description 1
- ZILUQQBNFFJRLB-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]thiophene-2-carboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CS1 ZILUQQBNFFJRLB-UHFFFAOYSA-N 0.000 description 1
- MFHQYQOIPCWNJA-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]thiophene-3-carboxamide Chemical compound C1CN(C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CSC=C1 MFHQYQOIPCWNJA-UHFFFAOYSA-N 0.000 description 1
- CBLBYJRMFVYXIO-UHFFFAOYSA-N n-[3-(1-propan-2-ylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]benzamide Chemical compound C1CN(C(C)C)CCC1C(C1=N2)=CNC1=CC=C2NC(=O)C1=CC=CC=C1 CBLBYJRMFVYXIO-UHFFFAOYSA-N 0.000 description 1
- SBBMTQVSAJNHCX-UHFFFAOYSA-N n-[3-(1-propan-2-ylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]propanamide Chemical compound C12=NC(NC(=O)CC)=CC=C2NC=C1C1CCN(C(C)C)CC1 SBBMTQVSAJNHCX-UHFFFAOYSA-N 0.000 description 1
- QKAOSXWKPYWJDP-UHFFFAOYSA-N n-[3-(1-propylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]propanamide Chemical compound C1CN(CCC)CCC1C1=CNC2=CC=C(NC(=O)CC)N=C12 QKAOSXWKPYWJDP-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNHVTXYLRVGMHD-UHFFFAOYSA-N n-butyl isocyanate Chemical compound CCCCN=C=O HNHVTXYLRVGMHD-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- ZWLPBLYKEWSWPD-UHFFFAOYSA-M o-toluate Chemical compound CC1=CC=CC=C1C([O-])=O ZWLPBLYKEWSWPD-UHFFFAOYSA-M 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- REEZZSHJLXOIHL-UHFFFAOYSA-N octanoyl chloride Chemical compound CCCCCCCC(Cl)=O REEZZSHJLXOIHL-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- QRSQRUVGXCMBSB-UHFFFAOYSA-N oxalic acid;3-piperidin-4-yl-1h-indol-5-ol Chemical compound OC(=O)C(O)=O.C12=CC(O)=CC=C2NC=C1C1CCNCC1 QRSQRUVGXCMBSB-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- JZHTVBSGBGDPAI-UHFFFAOYSA-N pent-3-enyl n-[3-(1-butan-2-ylpiperidin-4-yl)-1h-pyrrolo[3,2-b]pyridin-5-yl]carbamate Chemical compound C1CN(C(C)CC)CCC1C1=CNC2=CC=C(NC(=O)OCCC=CC)N=C12 JZHTVBSGBGDPAI-UHFFFAOYSA-N 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- XGISHOFUAFNYQF-UHFFFAOYSA-N pentanoyl chloride Chemical compound CCCCC(Cl)=O XGISHOFUAFNYQF-UHFFFAOYSA-N 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical group CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002717 polyvinylpyridine Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- DREJOBMXIQMQPB-UHFFFAOYSA-N propyl 4-[2-amino-3-[1-(2-methylpropyl)piperidin-4-yl]-1H-pyrrolo[3,2-b]pyridin-5-yl]-4-oxobutanoate Chemical compound CCCOC(=O)CCC(=O)C1=CC=C2C(=N1)C(=C(N2)N)C1CCN(CC1)CC(C)C DREJOBMXIQMQPB-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000005477 standard model Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- PORMUFZNYQJOEI-UHFFFAOYSA-N sumatriptan succinate Chemical compound OC(=O)CCC(O)=O.CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 PORMUFZNYQJOEI-UHFFFAOYSA-N 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- QTWBEVAYYDZLQL-UHFFFAOYSA-N thiophene-3-carbonyl chloride Chemical compound ClC(=O)C=1C=CSC=1 QTWBEVAYYDZLQL-UHFFFAOYSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000002271 trichotillomania Diseases 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Electroluminescent Light Sources (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3095096P | 1996-11-15 | 1996-11-15 | |
| US30950P | 1996-11-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2210463T3 true ES2210463T3 (es) | 2004-07-01 |
Family
ID=21856862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97309106T Expired - Lifetime ES2210463T3 (es) | 1996-11-15 | 1997-11-12 | Agonistas de 5-ht1f. |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US5817671A (https=) |
| EP (1) | EP0842934B1 (https=) |
| JP (1) | JP2001503774A (https=) |
| AT (1) | ATE253063T1 (https=) |
| AU (1) | AU5435298A (https=) |
| CA (1) | CA2271272A1 (https=) |
| CO (1) | CO4910133A1 (https=) |
| DE (1) | DE69725825T2 (https=) |
| DK (1) | DK0842934T3 (https=) |
| ES (1) | ES2210463T3 (https=) |
| ID (1) | ID18883A (https=) |
| IL (1) | IL129592A0 (https=) |
| NO (1) | NO991974L (https=) |
| PE (1) | PE14199A1 (https=) |
| PT (1) | PT842934E (https=) |
| WO (1) | WO1998020875A1 (https=) |
| ZA (1) | ZA979961B (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA989389B (en) * | 1997-11-14 | 2000-04-14 | Lilly Co Eli | Pyrrolo [3,2-b] pyridine processes and intermediates. |
| US5905084A (en) * | 1997-11-14 | 1999-05-18 | Eli Lilly And Company | 5-HTIF -agonists effective in treating migraine |
| US6133290A (en) * | 1998-07-31 | 2000-10-17 | Eli Lilly And Company | 5-HT1F agonists |
| GB9823845D0 (en) * | 1998-11-02 | 1998-12-23 | Lilly Co Eli | Pharmaceutical compounds |
| US6608079B1 (en) | 1998-12-11 | 2003-08-19 | Eli Lilly And Company | Indole derivatives and their use as 5-HT1F agonists |
| WO2003059884A1 (en) | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Modulators of lxr |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| TWI263497B (en) | 2002-03-29 | 2006-10-11 | Lilly Co Eli | Pyridinoylpiperidines as 5-HT1F agonists |
| ES2201899B1 (es) * | 2002-04-01 | 2005-06-01 | Almirall Prodesfarma, S.A. | Derivados de la azaindolilpiperidina como agentes antihistaminicos y antialergicos. |
| MXPA05011223A (es) | 2003-04-18 | 2006-01-26 | Lilly Co Eli | Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas 5-htif. |
| UA82711C2 (en) | 2003-09-12 | 2008-05-12 | Эли Лилли Энд Компани | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists |
| CA2546754A1 (en) * | 2003-11-21 | 2005-06-09 | Array Biopharma Inc. | Akt protein kinase inhibitors |
| DE602004008338T2 (de) | 2003-12-17 | 2008-05-29 | Eli Lilly And Co., Indianapolis | Substituierte (4-aminocyclohexen-1-yl) phenyl and (4-aminocyclohexen-1-yl) pyridinyl verbindungen als 5-ht1f agonisten |
| US8329701B2 (en) | 2006-07-06 | 2012-12-11 | Array Biopharma Inc. | Dihydrofuro pyrimidines as AKT protein kinase inhibitors |
| US8063050B2 (en) * | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| ATE532789T1 (de) | 2006-07-06 | 2011-11-15 | Array Biopharma Inc | Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren |
| EP2049500B1 (en) * | 2006-07-06 | 2011-09-07 | Array Biopharma, Inc. | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
| CN103396409B (zh) | 2007-07-05 | 2015-03-11 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
| CN101918373B (zh) * | 2007-07-05 | 2013-06-05 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
| US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
| NZ586346A (en) * | 2008-01-09 | 2012-02-24 | Array Biopharma Inc | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| US8853216B2 (en) * | 2008-01-09 | 2014-10-07 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor |
| PL2413933T5 (pl) | 2009-04-02 | 2021-10-18 | Colucid Pharmaceuticals, Inc. | 2,4,6-trifluoro-N-[6-(1-metylopiperydyno-4-karbonylo)pirydyn-2-ylo]benzamid do leczenia migreny drogą doustną lub dożylną |
| US8697876B2 (en) | 2010-04-02 | 2014-04-15 | Colucid Pharmaceuticals, Inc. | Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists |
| TR201815685T4 (tr) | 2011-04-01 | 2018-11-21 | Genentech Inc | Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları. |
| KR102021157B1 (ko) | 2011-04-01 | 2019-09-11 | 제넨테크, 인크. | Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법 |
| BG111544A (bg) | 2013-07-29 | 2015-01-30 | Николай Цветков | Субституирани бензамидни производни като in vitro mao-b инхибитори |
| LT3027603T (lt) * | 2013-08-02 | 2018-08-10 | Pfizer Inc. | Heterobicikloarilo rorc2 inhibitoriai ir jų panaudojimo būdai |
| MA40759A (fr) | 2014-09-26 | 2017-08-01 | Pfizer | Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation |
| DK3416964T3 (da) * | 2016-02-19 | 2021-02-22 | Phoenix Molecular Designs | 6-Oxo-N-(1-(benzyl)-1H-pyrazol-4-YL)-6,7,8,9-tetrahydropyrido[3',2':4,5]pyrrolo[1,2-A]pyrazin-2-carboxamid-derivater som P90 ribosomal S6 kinase- (RSK-) hæmmere til behandling af cancer |
| WO2020038435A1 (en) | 2018-08-24 | 2020-02-27 | Sunshine Lake Pharma Co., Ltd. | Pyridinylmethylenepiperidine derivatives and uses thereof |
| TWI826514B (zh) | 2018-09-04 | 2023-12-21 | 美商美國禮來大藥廠 | 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥 |
| US12378245B2 (en) | 2019-02-11 | 2025-08-05 | Phoenix Molecular Designs | Crystalline forms of an RSK inhibitor |
| TWI776175B (zh) | 2019-07-09 | 2022-09-01 | 美商美國禮來大藥廠 | 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3080374A (en) * | 1962-02-08 | 1963-03-05 | Abbott Lab | 2-guanidino-3-nitropyridine and derivatives thereof |
| MX19185A (es) * | 1989-01-20 | 1993-12-01 | Pfizer | Procedimiento para preparar 3-(1,2,5,6-tretrahidropiridil)-pirrolopiridinas. |
| US5521196A (en) * | 1994-10-05 | 1996-05-28 | Eli Lilly And Company | 5-HT1F agonists for the treatment of migraine |
| GB9423460D0 (en) * | 1994-11-21 | 1995-01-11 | Merck Sharp & Dohme | Therapeutic agents |
| US5521197A (en) * | 1994-12-01 | 1996-05-28 | Eli Lilly And Company | 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists |
| NZ305166A (en) * | 1995-03-20 | 1998-12-23 | Lilly Co Eli | 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments |
-
1997
- 1997-11-05 ZA ZA979961A patent/ZA979961B/xx unknown
- 1997-11-12 ES ES97309106T patent/ES2210463T3/es not_active Expired - Lifetime
- 1997-11-12 PT PT97309106T patent/PT842934E/pt unknown
- 1997-11-12 AT AT97309106T patent/ATE253063T1/de not_active IP Right Cessation
- 1997-11-12 EP EP97309106A patent/EP0842934B1/en not_active Expired - Lifetime
- 1997-11-12 DK DK97309106T patent/DK0842934T3/da active
- 1997-11-12 DE DE69725825T patent/DE69725825T2/de not_active Expired - Fee Related
- 1997-11-13 ID IDP973668A patent/ID18883A/id unknown
- 1997-11-13 CO CO97066711A patent/CO4910133A1/es unknown
- 1997-11-13 PE PE1997001023A patent/PE14199A1/es not_active Application Discontinuation
- 1997-11-13 AU AU54352/98A patent/AU5435298A/en not_active Abandoned
- 1997-11-13 WO PCT/US1997/020630 patent/WO1998020875A1/en not_active Ceased
- 1997-11-13 IL IL12959297A patent/IL129592A0/xx unknown
- 1997-11-13 CA CA002271272A patent/CA2271272A1/en not_active Abandoned
- 1997-11-13 JP JP52277798A patent/JP2001503774A/ja not_active Ceased
- 1997-11-14 US US08/969,851 patent/US5817671A/en not_active Expired - Fee Related
-
1998
- 1998-07-09 US US09/112,562 patent/US5998622A/en not_active Expired - Fee Related
- 1998-07-09 US US09/112,560 patent/US5919936A/en not_active Expired - Fee Related
-
1999
- 1999-04-26 NO NO991974A patent/NO991974L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0842934B1 (en) | 2003-10-29 |
| DE69725825D1 (de) | 2003-12-04 |
| AU5435298A (en) | 1998-06-03 |
| NO991974D0 (no) | 1999-04-26 |
| US5998622A (en) | 1999-12-07 |
| ZA979961B (en) | 1999-05-05 |
| CA2271272A1 (en) | 1998-05-22 |
| EP0842934A1 (en) | 1998-05-20 |
| US5919936A (en) | 1999-07-06 |
| PT842934E (pt) | 2004-03-31 |
| ID18883A (id) | 1998-05-20 |
| NO991974L (no) | 1999-04-26 |
| ATE253063T1 (de) | 2003-11-15 |
| DK0842934T3 (da) | 2004-03-08 |
| JP2001503774A (ja) | 2001-03-21 |
| CO4910133A1 (es) | 2000-04-24 |
| US5817671A (en) | 1998-10-06 |
| DE69725825T2 (de) | 2004-08-12 |
| IL129592A0 (en) | 2000-02-29 |
| PE14199A1 (es) | 1999-02-12 |
| WO1998020875A1 (en) | 1998-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2210463T3 (es) | Agonistas de 5-ht1f. | |
| ES2883285T3 (es) | Antagonistas de tlr7/8 y sus usos | |
| ES2209462T3 (es) | Agonistas de 5-ht1f. | |
| ES2219813T3 (es) | N-(1-nbutil-4-piperidinil)metil-3,4-dihidro-2h-1,3-oxazino-3,2-a-indol-10-carboxamida, o una de sus sales farmaceuticamente aceptables. | |
| ES2254964T3 (es) | Nuevos derivados de indolilpiperidina como potentes agentets antihistaminicos y antialergicos. | |
| KR100985995B1 (ko) | ５-ｈｔ１ｆ 효능제로서의 피리디노일피페리딘 | |
| ES2290782T3 (es) | Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuestos aferentes como inhibidores de la glucogeno fosforilasa en el tratamiento de la diabetes y de la obesidad. | |
| CA2802188C (en) | D2 antagonists, methods of synthesis and methods of use | |
| ES2685839T3 (es) | Inhibidores de RORC2 heterobicicloarilo y procedimientos de uso de los mismos | |
| ES2227500T3 (es) | (s)-4-amino.5-cloro-2-metoxi-n-(1-(1-(2-tetrahidrofuril-carbonil)-4-piperidinilmetil)-4-piperidinil) benzamina para el tratamaiento de desordenes de la motilidad gastrointestinal. | |
| WO1999055674A1 (en) | 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds | |
| ES2295017T3 (es) | Agonistas 5-ht1f. | |
| ES2199410T3 (es) | Carbazol carboxamidas como agonistas 5-ht1f. | |
| KR100777875B1 (ko) | 5-ｈｔ1ｆ 효능제로서의 치환된2-카르보닐아미노-6-피페리딘아미노피리딘 및 치환된1-카르보닐아미노-3-피페리딘아미노벤젠 | |
| TWI726916B (zh) | 治療性化合物及其使用方法 | |
| ES2198657T3 (es) | Pirrolo-(3,2-b)piridinas y su uso como agonistas de 5-ht1f. | |
| ES2478042T3 (es) | Derivado de amida y composición farmacéutica que contiene el mismo | |
| JPH08501293A (ja) | 医薬用ヘテロアリール化合物 | |
| ES2244243T3 (es) | Deerivados de quinazolinona. | |
| EP1082958A2 (en) | 5-HT1F agonists in chronic pain | |
| HK1010882A (en) | 5-ht1f agonists | |
| ES2291978T3 (es) | Compuestos de (4-aminociclohexen-1-il)fenilo y (4-aminociclohexen-1-il)piridinilo sustituidos como agonistas de 5-ht1f. | |
| HK1235103A1 (en) | D2 antagonists, methods of synthesis and methods of use | |
| BR112013024136A2 (pt) | ligandos de receptor de opióide e métodos de usar e fabricar os mesmos | |
| CZ20001716A3 (cs) | 5-HT1F agonisté |